PELICAN HEALTH | Linksium
Back to portfolio

PELICAN HEALTH

Incorporated startups

Ease of access to intestinal biomarkers

profilePhoto   Philippe Mattia
Linksium Contact Philippe Mattia +33 (0)4 57 13 81 65 philippe.mattia@linksium.fr
PELICAN HEALTH Thomas Sorenzo, CEO +33 (0)7 78 05 15 82 t.soranzo@pelican-health.com
Jannes jacobs 1349896 unsplash

Benefits

  • Non-invasive and biocompatible medical device enabling intestinal sampling

Key words

  • Capsule Intestine
  • Biomarkers Microbiota
  • Multiomic analysis

Intellectual Property

  • 2 patents

Partnerships & Rewards

  • 2021 i-Lab French Deeptech Innovation Competition Winner

Laboratory

  • TIMC-IMAG

Institutions

  • CNRS
  • GRENOBLE INP
  • UGA

Linksium Continuum

  • Maturation
  • Incubation
  • Acceleration

Results

  • Incorporated startups

Context

The gastrointestinal tract is a major organ in the human body. It secrets certain hormones and hosts a group of microorganisms (microbiota) which, when disturbed, are involved in a large number of pathologies. Access to this source of biomarkers is therefore a major issue.

Technology

The intestinal sampling device relies on a balance of forces between an internal material and an elastic envelope that surrounds it. On contact with the intestinal liquid, the internal polymer swells and confines the sample, which is then recovered by natural means.

Advantages

Today, protein and microbiological analyses are performed using faecal matter. However, this does not represent the real state of the intestine. Our device makes it possible to take a specific sample in the intestine in a non-invasive and painless manner.

State of progress

There is a Proof of Concept for this technology. The latest prototypes are in the pre-industrialisation phase. A clinical study on healthy volunteers has been carried out.

Applications

  • Looking for biomarkers in the intestinal tract
  • Accelerating the placing on the market of animal nutrition products
  • Validating the health benefits of new human nutrition products
  • Accelerating the clinical development of human therapeutic products
  • Diagnosing dysbiosis, i.e. intestinal microbial imbalances